Compare Inovio Pharmaceuticals Inc (INO) vs Toyota Motor Corp (TM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Toyota Motor Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Toyota Motor Corp trades at $181.09 (market cap $212.22B). The key difference: Toyota Motor Corp is far larger — about 2377.3× Inovio Pharmaceuticals Inc's market cap, and Toyota Motor Corp pays a 3.51% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | TM | |
|---|---|---|
Market Cap | $89.27M | $212.22B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $248.29 |
52-Week Low | $1.05 | $166.50 |
Enterprise Value | $60.28M | $376.42B |
Dividend Yield | — | 3.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Toyota Motor (TM) trades at $178.53, up 0.52% with neutral technical signals. The stock shows strong fundamentals with a low P/E of 9.73 and consistent earnings beats, including Q1 2026 EPS of $4.00 versus $3.11 expected. Recent news highlights a $3.6 billion Texas plant expansion announced July 6, 2026 (Reuters), signaling growth commitment. Cash flow trends show a 2025 dip but project recovery in 2026 with operating cash flow of $5.47 trillion.
Outlook is cautiously positive given undervaluation and hybrid vehicle demand, but risks include rising debt-to-asset ratios (41.29% in 2025) and margin pressure. Analyst consensus is mixed with 37.5% buy ratings, suggesting potential upside if execution aligns with expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Toyota Motor Corp
Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.
Read more on TM →
